MedTrace Logo

Negative Serology by Immunoenzymatic Test (EIA) in HIV-infected Children Treated Early With Antiretroviral in the ANRS-Pediacam Study: Pathophysiological Mechanisms

NCT06302933 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 451

Last updated 2025-01-30

No results posted yet for this study

Summary

The objective of the study is to identify the pathophysiological mechanisms responsible for the induction and maintenance of negative serologies by EIA tests in HIV-infected children treated early with HAART in the ANRS 12225-Pediacam III cohort in Cameroon

The hypothesis of better control of HIV infection through interactions between immunological, viral, and genetic factors was made to build the following objectives:

* Immunological aspect: lack of humoral response or immune activation
* Virological aspect: Reduced HIV reservoir size
* Determine the HLA phenotype in the different groups of children included and the KIR genotypes.

Conditions

  • HIV Infections

Interventions

BIOLOGICAL

Blood sampling

Blood samples collected from children followed in the Pediacam III ANRS12225 cohort

Sponsors & Collaborators

  • Centre Pasteur du Cameroun

    collaborator OTHER

  • Centre Mère et Enfant de la Fondation Chantal Biya

    collaborator OTHER

  • Centre Hospitalier D'essos

    collaborator OTHER

  • Hospital General De Douala

    collaborator OTHER

  • CH Orléans

    collaborator UNKNOWN

  • Institut Pasteur

    collaborator INDUSTRY

  • Hopital Universitaire Robert-Debre

    collaborator OTHER

  • Université Paris-Sud

    collaborator OTHER

  • ANRS, Emerging Infectious Diseases

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-02
Primary Completion
2025-08-30
Completion
2025-08-30

Countries

  • Cameroon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06302933 on ClinicalTrials.gov